Veterinary vaccines Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3039
Veterinary Vaccines Market size is projected to experience significant growth from 2018 to 2024.
Rising burden of zoonotic diseases across the globe will drive veterinary vaccines market growth over the forecast timeline. Annually, thousands of Americans get sick as they acquire zoonotic diseases. According to Center for disease Control and Prevention, every 6 out of 10 infectious diseases in humans is spread from animals. In addition, children below 5 years and adults above 65 years are more susceptible to zoonotic diseases. As American demographics suggest that there is larger geriatric population base, the number of people suffering from zoonotic disease will increase, thereby positively influence market growth in upcoming years.
Increasing number of infectious diseases in companion animals such as influenza virus and respiratory diseases will lead to increasing need for veterinary vaccines in the future. As per the surveillance carried out by Small Animal Veterinary Surveillance Network (SAVSNET), In 2017, consultations for gastrointestinal disease constituted on average 19 per 1000 weekly consultations in cats and 29 per 1000 weekly consultations in dogs. As number of infectious diseases is increasing the need for veterinary vaccination should increase in the future.
Various policies for prevention and control of infectious and zoonotic diseases will boost veterinary vaccines industry. Implementation of international polices such as One Health approach in developing and developed countries will significantly improve animal healthcare. An important aspect of One Health approach includes use of vaccines for controlling spread of infectious disease that will substantially boost industry growth over forecast timeframe.
However, lack of lack of awareness for prevention of infectious diseases among animals may restrict growth of veterinary vaccines market. High inventory cost for vaccine storage and lack of availability of skilled animal health personnel can hamper market growth.
Recombinant vaccines will show tremendous growth during the forecast period owing to better relief offered to animals. Cost of production of recombinant or DNA vaccines is relatively low, thereby leading to its wide-scale acceptability. Safe and effective prevention coupled with low production cost will favor segmental growth.
Parenteral route of administration segment will grow at a momentous rate as a result of quick response after administration and prolonged release of vaccines can also be achieved. Adoption of novel techniques for development of vaccines administered via parenteral route having few side effects will drive the demand segmental growth.
Companion animal vaccine segment will witness remarkable growth over the forecast period due to increasing importance of pet animal care. Furthermore, vaccination is the major resolve for prevention and treatment of diseases in companion animals. Development of advanced vaccination for companion animals will have positive impact on segmental growth.
U.S. veterinary vaccines will dominate market owing to increasing importance of safe animal food supply, prevention of diseases transmission across the nation. Also, increasing awareness among the U.S. population regarding health of livestock and companion animals will favor regional growth. increasing ownership of companion animals and developed vaccination programs are factors propelling the market in U.S. during projected timeframe.
Some of the prominent players of global veterinary vaccines market include Bayer Pharma Ag, Boehringer Ingelheim Animal Health GmbH, Ceva Sante Animale, Elanco, Eli Lilly & Company, Hester Biosciences Ltd., HIPRA, Indian Immunologicals Limited, Merck & Co., Phibro Animal Health Corp., Virbac and Zoetis Animal Healthcare. The competitors focus on product launch, merger and acquisitions to strengthen market position. For instance, in September 2017, Merck Animal Health launched Innovax-ND-IBD live vaccine that protects chickens from various infectious disease. This will fortify company’s market position and expand its product portfolio and strengthen its market position.
Veterinary vaccines market by type, 2013-2024 (USD Million)
- Attenuated vaccine
- Inactivated vaccines
- Recombinant vaccines
- Toxoid vaccines
- Therapeutic biologics
Veterinary vaccines market by route of administration, 2013-2024 (USD Million)
Veterinary vaccines market by animal type, 2013-2024 (USD Million)
- Livestock vaccines
- Companion animal vaccines
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Bayer Pharma Ag
- Boehringer Ingelheim Animal Health GmbH
- Ceva Sante Animale
- Eli Lilly & Company
- Hester Biosciences Ltd
- Indian Immunologicals Limited
- Merck & Co.
- Phibro Animal Health Corp.
- Zoetis Animal Healthcare
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability